Citation Impact
Citing Papers
CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients
2008
Essential roles of DC-derived IL-15 as a mediator of inflammatory responses in vivo
2006
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
2010 StandoutNobel
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
2007 StandoutScienceNobel
Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
2007 StandoutNobel
Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells
2005 StandoutNobel
Molecular Cloning of the Gene Encoding Rabbit Tumor Necrosis Factor
1986
Molecular Cloning and Expression in Escherichia coli of the cDNA Coding for Rabbit Tumor Necrosis Factor
1986
Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors.
2007
Hallmarks of Cancer: The Next Generation
2011 Standout
mRNA expression of leukemia‐associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies
2003
Cancer/testis (CT) antigens: Potential targets for immunotherapy
2009
Autoantibodies Against Cancer Antigens
2009
Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity
2006
The Effect of Dietary Supplementation with n—3 Polyunsaturated Fatty Acids on the Synthesis of Interleukin-1 and Tumor Necrosis Factor by Mononuclear Cells
1989 Standout
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
1997 StandoutNature
Physiological Responses to Cachectin
2007
Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient
2008
TNF? and the TNF receptor superfamily: Structure-function relationship(s)
2000
Antibody response against NY‐ESO‐1 in CHP‐NY‐ESO‐1 vaccinated patients
2007
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptors
1994
Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen
2006
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
2002
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions
2005
Global cancer statistics
2011 Standout
Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation
1993
Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α
1987 StandoutNature
Control of cross‐presentation during dendritic cell maturation
2004
Human tumor antigens for cancer vaccine development
1999
Taking dendritic cells into medicine
2007 StandoutNatureNobel
Identification of a cold receptor reveals a general role for TRP channels in thermosensation
2002 StandoutNatureNobel
In vivo antigen delivery by aSalmonella typhimurium type III secretion system for therapeutic cancer vaccines
2006
NY‐ESO‐1: Review of an Immunogenic Tumor Antigen
2006
Dendritic Cells In Vivo: A Key Target for a New Vaccine Science
2008 StandoutNobel
Interleukin‐12 is required for interferon‐γ production and lethality in lipopolysaccharide‐induced shock in mice
1995
Cancer/testis antigens, gametogenesis and cancer
2005 Standout
MHC class II-associated variation in the production of tumor necrosis factor in mice and humans: Relevance to the pathogenesis of autoimmune diseases
1991
Split T Cell Tolerance against a Self/Tumor Antigen: Spontaneous CD4+ but Not CD8+ T Cell Responses against p53 in Cancer Patients and Healthy Donors
2011
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012 StandoutNatureNobel
Points of control in inflammation
2002 StandoutNature
Dendritic cells and the control of immunity
1998 StandoutNatureNobel
The TNF and TNF Receptor Superfamilies
2001 Standout
TRAF2 Deficiency Results in Hyperactivity of Certain TNFR1 Signals and Impairment of CD40-Mediated Responses
1999
Monoclonal antibodies for cancer immunotherapy
2009
A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain
1995
Inferences, questions and possibilities in Toll-like receptor signalling
2004 StandoutNatureNobel
The Tumor Necrosis Factor Ligand and Receptor Families
1996 StandoutNobel
An Essential Role for Ectodomain Shedding in Mammalian Development
1998 Science
The Structure of Tumor Necrosis Factor-α at 2.6 Å Resolution
1989
Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1.
1986
Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
2000
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
2009
Control of Cachectin (Tumor Necrosis Factor) Synthesis: Mechanisms of Endotoxin Resistance
1986 StandoutScienceNobel
A Critical Role for Syk Protein Tyrosine Kinase in Fc Receptor-Mediated Antigen Presentation and Induction of Dendritic Cell Maturation
2003
Epstein-Barr virus-associated antibody patterns in carcinoma of the post-nasal space.
1969
The Enigmatic Epidemiology of Nasopharyngeal Carcinoma
2006 Standout
Production of an anti-tumour cytotoxin by human monocytes.
1981
Tumor Necrosis Factor (TNF)
1985 StandoutScience
Extinction of the tumor necrosis factor locus, and of genes encoding the lipopolysaccharide signaling pathway.
1993 StandoutNobel
Recombinant human TNF induces production of granulocyte–monocyte colony-stimulating factor
1986 Nature
Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
2003
Constitutive versus Activation-dependent Cross-Presentation of Immune Complexes by CD8+ and CD8− Dendritic Cells In Vivo
2002
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
2007
Seromic profiling of ovarian and pancreatic cancer
2010
HMG-1 as a Late Mediator of Endotoxin Lethality in Mice
1999 StandoutScience
Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon
1985 Nature
Identity of differentiation inducing factor and tumour necrosis factor
1986 Nature
The CD8+ Dendritic Cell Subset Selectively Endocytoses Dying Cells in Culture and In Vivo
2002 StandoutNobel
Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
2003
Human tumor necrosis factor. Production, purification, and characterization.
1985
Cachectin and tumour necrosis factor as two sides of the same biological coin
1986 StandoutNatureNobel
Constitutive activity of the tumor necrosis factor promoter is canceled by the 3' untranslated region in nonmacrophage cell lines; a trans-dominant factor overcomes this suppressive effect.
1992 StandoutNobel
Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins.
2001
Differential Reactivity of Human Serums with Early Antigens Induced by Epstein-Barr Virus
1970 Science
Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression.
1986
DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8 + T cells in a spectrum of human MHC I haplotypes
2007 StandoutNobel
The Three Es of Cancer Immunoediting
2004 Standout
Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro.
1986
CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients
2005
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.
1988 StandoutNobel
Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
2010
Presence of EB Virus Nucleic Acid Homology in a “Virus-free” Line of Burkitt Tumour Cells
1970 StandoutNatureNobel
Generation and characterization of a lipopolysaccharide-induced and serum-derived cytotoxic factor for tumor cells
1980
Tumor necrosis factor induction by Sendai virus.
1986
Activation of human macrophages. Comparison of other cytokines with interferon-gamma.
1984
Induction of Necrotic-Like Cell Death by Tumor Necrosis Factor Alpha and Caspase Inhibitors: Novel Mechanism for Killing Virus-Infected Cells
2000
Shock and Tissue Injury Induced by Recombinant Human Cachectin
1986 StandoutScienceNobel
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Differential expression of cancer testis genes in histological subtypes of non-Hodgkin's lymphomas.
2003
Macrophages as a source of tumoricidal activity (tumor-necrotizing factor)
1980
In vitro production of rabbit macrophage tumor cell cytotoxin
1983
PURIFICATION AND PARTIAL AMINO ACID SEQUENCE OF RABBIT TUMOR NECROSIS FACTOR
1985
Macrophage-mediated cytotoxicity: role of a soluble macrophage cytotoxic factor similar to lymphotoxin and tumor necrosis factor.
1983
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
2012 StandoutNobel
Immune complex–mediated antigen presentation induces tumor immunity
2002
Analysis of the B‐cell repertoire against antigens expressed by human neoplasms
2002
Tumour-necrosis factor from the rabbit. V. Synthesis in vitro by mononuclear phagocytes from various tissues of normal and BCG-injected rabbits
1981
Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice
1984
Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor.
1991
Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.
1986
Tumour-necrosis factor from the rabbit. I. Mode of action, specificity and physicochemical properties
1978
Antiviral effects of recombinant tumour necrosis factor in vitro
1986 Nature
Lipopolysaccharide-Induced Cytokine Cascade and Lethality in LTα/TNFα-Deficient Mice
1997
Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin
1985 StandoutScienceNobel
Production of tumour necrosis factor by mastocytoma P815 cells.
1990
Natural killer (NK) cell-derived hematopoietic colony-inhibiting activity and NK cytotoxic factor. Relationship with tumor necrosis factor and synergism with immune interferon.
1985
Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon.
1986
Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
2005 Standout
IFN-γ enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation
2004
Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor
1985 Nature
Persisting oncogenic herpesvirus induced by the tumour promoter TPA
1978 StandoutNatureNobel
Distinct Roles of Lymphotoxin α and the Type I Tumor Necrosis Factor (TNF) Receptor in the Establishment of Follicular Dendritic Cells from Non–Bone Marrow–derived Cells
1997
Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes.
1987
Induction of Manganous Superoxide Dismutase by Tumor Necrosis Factor: Possible Protective Mechanism
1988 Science
Immune complex–mediated antigen presentation induces tumor immunity
2002
Cachectin: More Than a Tumor Necrosis Factor
1987 StandoutNobel
Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific.
1991
Commentary
2002
A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens
1998
Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells.
1986
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.
1986 StandoutNobel
Phase I study of recombinant tumor necrosis factor in cancer patients.
1987
Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance
2002 StandoutNobel
Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells.
1985
RELATION BETWEEN EPSTEIN-BARR VIRAL AND CELL MEMBRANE IMMUNOFLUORESCENCE IN BURKITT TUMOR CELLS
1969
Molecular Cloning, Characterization, and Expression of TNF cDNA and Gene from Japanese FlounderParalychthys olivaceus
2000
Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage
2006
Human Lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization
1985
Epitope Landscape in Breast and Colorectal Cancer
2008 StandoutNobel
Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor.
1985
An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
1996 StandoutScienceNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance
2002 StandoutNobel
Viruses in Human Cancers
1991 StandoutScienceNobel
Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1.
1986
Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in Vitro
1985 StandoutScience
Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity
1984 Nature
Tumour necrosis factors α and β inhibit virus replication and synergize with interferons
1986 Nature
HUMAN T CELL RESPONSES AGAINST MELANOMA
2005
Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor.
1985
Cellular receptor for 125I-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity.
1985
MATURE T LYMPHOCYTE APOPTOSIS—Immune Regulation in a Dynamic and Unpredictable Antigenic Environment
1999
The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity.
1992
Effect of tumour necrosis factor on cultured human melanoma cells
1975 Nature
Molecular cloning of mouse tumour necrosis factor cDNA and its eukaryotic expression
1985
The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity.
1988
Partial purification of a serum factor that causes necrosis of tumors.
1976
Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity.
1990
Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition.
1985
DEVELOPMENT AND MATURATION OF SECONDARY LYMPHOID TISSUES
1999
Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations
2002
Inducing Tumor Immunity through the Selective Engagement of Activating Fcγ Receptors on Dendritic Cells
2002
Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae.
1986
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
2006
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
2008 StandoutNobel
Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor
1989
Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes
1998
Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor
1985
Secretory products of macrophages.
1987 Standout
Tolerogenic Dendritic Cells
2003 StandoutNobel
TUMOR NECROSIS FACTOR RECEPTOR AND Fas SIGNALING MECHANISMS
1999
Toll-like Receptor 9–Dependent and –Independent Dendritic Cell Activation by Chromatin–Immunoglobulin G Complexes
2004
Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers.
1986
Role of tumor necrosis factor-alpha in lipopolysaccharide-induced pathologic alterations.
1990
Immune complex–mediated antigen presentation induces tumor immunity
2002
Effects of recombinant tumor necrosis factor on proliferation and differentiation of leukemic and normal hemopoietic cells in vitro. Relationship to cell surface receptor.
1986
Purification of rabbit tumor necrosis factor
1985
Intratumoral T-Cell Infiltrates and MHC Class I Expression in Patients with Stage IV Melanoma
2005
Characterization of macrophage function in Mycobacterium lepraemurium‐infected mice: sensitivity of mice to endotoxin and release of mediators and lysosomal enzymes after endotoxin treatment
1983
Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin
1984 Nature
Identity of tumour necrosis factor and the macrophage-secreted factor cachectin
1985 StandoutNatureNobel
T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells
2002
Immune Therapy for Cancer
2008
Molecular Cloning of the Complementary DNA for Human Tumor Necrosis Factor
1985 Science
Role of first stimulating agents in the production of tumor necrosis factor
1984
Epstein–Barr Virus in Burkitt's Lymphoma and Nasopharyngeal Carcinoma: EBV DNA in Biopsies of Burkitt Tumours and Anaplastic Carcinomas of the Nasopharynx
1970 StandoutNatureNobel
Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.
1985 StandoutNobel
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
2000
Targeting Apoptotic Tumor Cells to FcγR Provides Efficient and Versatile Vaccination Against Tumors by Dendritic Cells
2003
Dendritic Cell Surface Calreticulin Is a Receptor for NY-ESO-1: Direct Interactions between Tumor-Associated Antigen and the Innate Immune System
2006
Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line.
1985
Survey of naturally occurring CD4 + T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses
2003
Tumour-necrosis factor from the rabbit. II. Production by monocytes
1978
Works of Barbara Williamson being referenced
Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer
2005
Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours
2000
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
2001
Identification of cancer/testis genes by database mining and mRNA expression analysis
2002
Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9
2000
Antigens recognized by autologous antibody in patients with renal-cell carcinoma
1999
Characterization of human colon cancer antigens recognized by autologous antibodies
1998
Isoforms of the human PDZ-73 protein exhibit differential tissue expression
1999
PRECIPITATING ANTIBODY IN HUMAN SERUM TO AN ANTIGEN PRESENT IN CULTURED BURKITT'S LYMPHOMA CELLS
1966
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
1997
Purification and characterization of a human tumor necrosis factor from the LuKII cell line.
1985
Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression.
2001
Characterization of tumor necrosis factor-deficient mice
1997
Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells
2002
Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor.
1986
High affinity binding of 125I-labeled human tumor necrosis factor (LuKII) to specific cell surface receptors.
1985
Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon.
1983
An endotoxin-induced serum factor that causes necrosis of tumors.
1975 Standout
Immunomic analysis of human sarcoma
2003
Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancer.
2004
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
2003
Endotoxin-Induced Tumor Necrosis Factor
1980
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
2003
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation
2005